Education Blog for Healthcare Professionals

Archive for the ‘Guideline’ Category

Bleeding on Antithrombotics: Reversal Protocol 2016

| Bleeding, Guideline, Uncategorized | Comments Off on Bleeding on Antithrombotics: Reversal Protocol 2016

Stephan Moll, MD writes…  Our medical center (University of North Carolina Hospitals,  Chapel Hill)  has put together a comprehensive “Emergent Anticoagulation Reversal Guideline” for our local use, updated since its last edition in 2014 with information about Pradaxa® reversal (with Praxbind®).  It is  a practical, clinical how-to document (2016 PDF here ). Colleagues and hospitals are welcome to take the document,  modify it, and apply it to their institution – there are no copyright concerns.

 

Disclosures: I have been a consultant on one occasion for Boehringer-Ingelheim.

Last updated: May 11th, 2016

New Comprehensive Clinical Guidance on VTE Treatment

| Anticoagulants, Guideline, Therapy, Thrombophilias, Uncategorized | Comments Off on New Comprehensive Clinical Guidance on VTE Treatment

Stephan Moll, MD writes… A new consensus guidance on management of venous thromboembolism (VTE) – link here – was published today, Jan 18th, 2016, in the Journal of Thrombosis and Thrombolysis.  The publication contains 13 chapters on various aspects of VTE Read the rest of this entry »

ACCP Guideline for DVT and PE Treatment: New Edition, 2016

| Anticoagulants, Aspirin, Plavix, Aggrenox, Tiklid, Persantine, Edoxaban, Eliquis, Guideline, Pradaxa (dabigatran), Therapy, Uncategorized, Xarelto (Rivaroxaban) | Comments Off on ACCP Guideline for DVT and PE Treatment: New Edition, 2016

The ACCP Chest Guidelines have been the main guide over the last more than 2 decades for evidence-based recommendations on best management of anticoagulants for various indications, including DVT and PE.  The 10th edition of the chapter on DVT and PE management was published in Jan 2016 [ref 1]. Unfortunately, the guideline is not available for non-subscribers. Read the rest of this entry »

VTE Prophylaxis in Hospitalized Patients: Guidance Document

| Guideline, Prevention, Uncategorized | Comments Off on VTE Prophylaxis in Hospitalized Patients: Guidance Document

Stephan Moll, MD writes (on 12/5/2014)… Venous thromboembolism (VTE) prophylaxis in hospitalized patients is important; it is also mandated by the Joint Commission [ref].  We have developed at the University of North Carolina (UNC) a guidance document (link here; UNC VTE prophylaxis guidance document) as a resource for our health care professionals to assist in making evidence-based decisions on which patients to give what type of VTE prophylaxis.

Recommendations provided in this document are a reflection of current guidelines, clinical evidence, and UNC institutional initiatives, but are not intended to replace clinical judgment or patient evaluation.  Readers are welcome to use this document for their institution or practice – using it as is or modifying it.

References

Joint Commission VTE measures (link here)

Disclosures: None

Last updated: Dec 5th, 2014

Difficulty in Diagnosing Recurrent DVT – Clinical Guidance

| Diagnosis, Guideline, Uncategorized | Comments Off on Difficulty in Diagnosing Recurrent DVT – Clinical Guidance

Stephan Moll, MD writes….  Recurrent DVT can be challenging to diagnose, as it may be difficult on Doppler ultrasound to tell chronic changes from additional new clot.  A guidance statement from the ISTH (International Society for Thrombosis and Haemostasis) published this week (May 18th, 2013) provides solid, clinically useful, evidence-based recommendations Read the rest of this entry »

Apixaban (Eliquis) – Hospital Guideline

| Anticoagulants, Eliquis, Guideline, Therapy, Uncategorized | Comments Off on Apixaban (Eliquis) – Hospital Guideline

Stephan Moll, MD writes…

Apixaban (Eliquis®) is FDA-approved for the prevention of  stroke and systemic arterial thromboembolism in patients with atrial fibrillation (Clot Connect discussion of the approval on  Dec 28th, 2012 is here).  Here is the management guideline for apixaban Read the rest of this entry »

ACCP 2012 Guidelines: A Great, New, User-Friendly Summary

| Guideline, Uncategorized | Comments Off on ACCP 2012 Guidelines: A Great, New, User-Friendly Summary

Stephan Moll, MD writes…  The more than 20 chapters and 801 pages of the respected 2012 ACCP Antithrombotic Therapy Guidelines – beautifully evidence-based, but always very cumbersome to read for the clinician looking for quick management guidance -, have now been summarized by the ACCP into a visually appealing, uncluttered, clinician-user-friendly document, referred to as “ACCP 2012 Reference Guide” (link to it here).  This was a much-needed development.  The only thing missing now is that one can buy this (90 page summary) as a hard copy for even better, i.e. quicker reference.  This is a highly recommended document for anybody involved in clinical decision-making in regard to antithrombotics in patients at risk for or with established arterial or venous thromboembolism. A very nice, new resource. Read the rest of this entry »

New ACCP Guidelines – DVT and PE: Highlights and Summary

| Anticoagulants, Deep Vein Thrombosis (DVT), Guideline, Pulmonary Embolism, Uncategorized | Comments Off on New ACCP Guidelines – DVT and PE: Highlights and Summary

Stephan Moll, MD writes…  This month the American College of Chest Physicians (ACCP) published its new (2012) guidelines regarding anticoagulation and management of various thrombotic disorders, replacing the 2008 edition. The details of the new guidelines can be found here Read the rest of this entry »